Literature DB >> 9450527

Assessing genetic markers of tumour progression in the context of intratumour heterogeneity.

J A Chapman1, E Wolman, S R Wolman, Y Remvikos, S Shackney, D E Axelrod, H Baisch, I J Christensen, R A White, L S Liebovitch, D H Moore, F M Waldman, C J Cornelisse, T V Shankey.   

Abstract

This is a report from the Kananaskis working group on quantitative methods in tumour heterogeneity. Tumour progression is currently believed to result from genetic instability and consequent acquisition of new genetic properties in some of the tumour cells. Cross-sectional assessment of genetic markers for human tumours requires quantifiable measures of intratumour heterogeneity for each parameter or characteristic observed; the relevance of heterogeneity to tumour progression can best be ascertained by repeated assessment along a tumour progressional time line. This paper outlines experimental and analytic considerations that, with repeated use, should lead to a better understanding of tumour heterogeneity, and hence, to improvements in patient diagnosis and therapy. Four general principles were agreed upon at the Symposium: (1) the concept of heterogeneity requires a quantifiable definition so that it can be assessed repeatably; (2) the quantification of heterogeneity is necessary so that testable hypotheses may be formulated and checked to determine the degree of support from observed data; (3) it is necessary to consider (a) what is being measured, (b) what is currently measurable, and (c) what should be measured; and (4) the proposal of working models is a useful step that will assist our understanding of the origins and significance of heterogeneity in tumours. The properties of these models should then be studied so that hypotheses may be refined and validated.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9450527     DOI: 10.1002/(sici)1097-0320(19980101)31:1<67::aid-cyto9>3.0.co;2-g

Source DB:  PubMed          Journal:  Cytometry        ISSN: 0196-4763


  3 in total

1.  Avoiding Pitfalls in the Statistical Analysis of Heterogeneous Tumors.

Authors:  David E Axelrod; Naomi Miller; Judith-Anne W Chapman
Journal:  Biomed Inform Insights       Date:  2009-01-01

2.  Intra-tumoral distribution of Ki-67 and Cyclin D1 in ER+ mammary carcinoma: quantitative evaluation.

Authors:  Mohammedi Latifa; Djillali Doula Fatima; Mesli Farida; Senhadji Rachid
Journal:  Afr Health Sci       Date:  2021-03       Impact factor: 0.927

3.  Multi-Color Spectral Transcript Analysis (SPECTRA) for Phenotypic Characterization of Tumor Cells.

Authors:  Joanne H Hsu; Jingly F Weier; Heinz-Ulrich G Weier; Yuko Ito
Journal:  Biomolecules       Date:  2013-02-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.